{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:28:21Z","timestamp":1765758501800,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"19","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2018,1,31]]},"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare ticagrelor and prasugrel with clopidogrel for recurrent fatal and non-fatal myocardial infarction (reMI) in real-life conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Case-referent study using the Pharmacoepidemiological General Research eXtension (PGRx)-acute coronary syndrome (ACS) registry. Cases were patients with reMI from a cohort with index ACS or external to the cohort (same sites). Referents from the cohort, without recurrent event, were matched on index ACS type and date, age and sex with reMI cases. Multivariate conditional logistic regression assessed the OR (95%\u2009CI) for reMI associated with ticagrelor and prasugrel vs clopidogrel, adjusted for aspirin use and cardiovascular risk factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>1047 cases and 2234 matched referents were included. Compared with clopidogrel, ticagrelor and prasugrel were associated with respective ORs of 0.65 (95% CI 0.52 to 0.81) and 0.71 (95% CI 0.53 to 0.96) for reMI occurrence. ORs for ticagrelor and prasugrel vs clopidogrel were: 0.50 (95% CI 0.38 to 0.67) and 0.66 (95% CI 0.45 to 0.95), 0.39 (95% CI 0.24 to 0.62) and 0.44 (95% CI 0.26 to 0.75), 0.63 (95% CI 0.43 to 0.92) and 1.20 (95% CI 0.69 to 2.07), 1.11 (95% CI 0.72 to 1.72) and 0.82 (95% CI 0.44 to 1.54) when index ACS was a first MI, a first ST-elevated MI (STEMI), a first non-STEMI and a recurrent ACS, respectively, and 0.63 (95% CI 0.45 to 0.87) and 0.77 (95% CI 0.41 to 1.45) for patients aged \u226570 \u2009years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This real-world study showed a significant reduction of reMI with new antiplatelets compared with clopidogrel, ticagrelor being associated with a greater decrease of risk notably for first, either STEMI or non-STEMI. The larger magnitude of effect may be attributed to potential residual confounding or higher effectiveness compared with efficacy reported in trials (EMA Post Authorisation Study Registry Number EUPAS5905).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2017-312534","type":"journal-article","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T12:20:39Z","timestamp":1520943639000},"page":"1583-1592","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction"],"prefix":"10.1136","volume":"104","author":[{"given":"Lamiae","family":"Grimaldi-Bensouda","sequence":"first","affiliation":[{"name":"Pharmacoepidemiology, PGRx Study Group, PGRx, Paris, France"},{"name":"London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Danchin","sequence":"additional","affiliation":[{"name":"Cardiologie, H\u00f4pital europ\u00e9en Georges-Pompidou, Universit\u00e9 Ren\u00e9 Descartes, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Dallongeville","sequence":"additional","affiliation":[{"name":"Epidemiologie, Institut Pasteur de Lille; INSERM 1167; Universit\u00e9 de Lille, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Falissard","sequence":"additional","affiliation":[{"name":"Statistique, CESP INSERM U1018, Universit\u00e9 Paris-Sud, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Furber","sequence":"additional","affiliation":[{"name":"Laboratoire MITOVASC \u2019Physiopathologie Cardiovasculaire et Mitochondriale', Facult\u00e9 de M\u00e9decine d\u2019Angers; Service de Cardiologie, UMR CNRS 6015 \u2013 INSERM U1083, Centre hospitalo-universitaire (CHU) de Angers, Angers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Cottin","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, CHU Dijon, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Bonello","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, CHU de Marseille, Aix-Marseille Universit\u00e9, Assistance-Publique H\u00f4pitaux de Marseille; MARS cardio, Mediterranean Association For Research And Studies In Cardiology, H\u00f4pital Nord, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Morel","sequence":"additional","affiliation":[{"name":"P\u00f4le d\u2019activit\u00e9 M\u00e9dico-Chirurgicale Cardiovasculaire, Nouvel H\u00f4pital Civil, Universit\u00e9 de Strasbourg, Strasbourg, France"},{"name":"Unit\u00e9 INSERM T770, Le Kremlin Bic\u00eatre, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Leclercq","sequence":"additional","affiliation":[{"name":"Cardiologie, Centre Hospitalier Universitaire de Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Puymirat","sequence":"additional","affiliation":[{"name":"Cardiologie, H\u00f4pital europ\u00e9en Georges-Pompidou, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahmi","family":"Ghanem","sequence":"additional","affiliation":[{"name":"Cardiologie, Hospital of Ch\u00e2teauroux, Ch\u00e2teauroux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Delarche","sequence":"additional","affiliation":[{"name":"Centre hospitalier Fran\u00e7ois Mitterrand, Pau, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Benichou","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Biostatistique, University Hospital of Rouen and U1219, University of Rouen, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucien","family":"Abenhaim","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology, Analytica LA-SER, London, UK"},{"name":"London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"2025092102295135000_104.19.1583.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"2025092102295135000_104.19.1583.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000134"},{"key":"2025092102295135000_104.19.1583.3","unstructured":"AstraZeneca AB . Product information. Brilique. 2016. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001241\/human_med_001398.jsp&mid=WC0b01ac058001d124 (accessed 2Mar 2017)."},{"key":"2025092102295135000_104.19.1583.4","unstructured":"Lilly SA . Product information. Efient. 2016. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000984\/human_med_000756.jsp&mid=WC0b01ac058001d124 (accessed 2 Mar 2017)."},{"key":"2025092102295135000_104.19.1583.5","unstructured":"Sanofi Winthrop Industrie. Product monograph. Plavix. 2017. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000174\/human_med_000979.jsp&mid=WC0b01ac058001d124 (accessed 2 Mar 2017)."},{"key":"2025092102295135000_104.19.1583.6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/FJC.0000000000000451","article-title":"Meta-analysis of Comparison of the Newer P2Y12 Inhibitors (Oral Preparation or Intravenous) to Clopidogrel in Patients With Acute Coronary Syndrome","volume":"69","author":"Zhang","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025092102295135000_104.19.1583.7","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.2174\/1381612822666160608114424","article-title":"P2Y12 Receptor Antagonists: Which One to Choose? A Systematic Review and Meta-Analysis","volume":"22","author":"Briasoulis","year":"2016","journal-title":"Curr Pharm Des"},{"key":"2025092102295135000_104.19.1583.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.05.058"},{"key":"2025092102295135000_104.19.1583.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202972"},{"key":"2025092102295135000_104.19.1583.10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijcard.2013.08.127","article-title":"Real-life effectiveness of statins in the prevention of first acute coronary syndrome in France: a prospective observational study","volume":"169","author":"Grimaldi-Bensouda","year":"2013","journal-title":"Int J Cardiol"},{"key":"2025092102295135000_104.19.1583.11","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2011.222448"},{"key":"2025092102295135000_104.19.1583.12","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/pds.2055","article-title":"Agreement between patients' self-report and physicians' prescriptions on cardiovascular drug exposure: the PGRx database experience","volume":"19","author":"Grimaldi-Bensouda","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025092102295135000_104.19.1583.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs184"},{"key":"2025092102295135000_104.19.1583.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu160"},{"key":"2025092102295135000_104.19.1583.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"2025092102295135000_104.19.1583.16","doi-asserted-by":"publisher","DOI":"10.2307\/2531050"},{"key":"2025092102295135000_104.19.1583.17","doi-asserted-by":"crossref","unstructured":"Sahl\u00e9n A , Varenhorst C , Lagerqvist B , et al . Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J 2016:37:3335\u201342 (accessed 19 Jul 2016).","DOI":"10.1093\/eurheartj\/ehw284"},{"key":"2025092102295135000_104.19.1583.18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/09537104.2017.1280601","article-title":"Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive \u2019real-world' patients","volume":"28","author":"Gosling","year":"2017","journal-title":"Platelets"},{"key":"2025092102295135000_104.19.1583.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.12.029"},{"key":"2025092102295135000_104.19.1583.20","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12907"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2017-312534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T09:30:00Z","timestamp":1758447000000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2017-312534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":20,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2018,9,13]]},"published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1136\/heartjnl-2017-312534"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2017-312534","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"type":"print","value":"1355-6037"},{"type":"electronic","value":"1468-201X"}],"subject":[],"published":{"date-parts":[[2018,3,13]]}}}